2026-04-04T00:14:54Zhttps://recercat.cat/oai/request

oai:recercat.cat:2445/1760482025-12-04T21:15:32Zcom_2072_1057col_2072_478781col_2072_478917

00925njm 22002777a 4500 dc Boyer Díaz, Zoe author Domingo i Pedrol, Joan Carles author De Gregorio, Estefanía author Manicardi, Nicolò author Aristu Zabalza, Peio author Cordobilla, Begoña author Abad Jordà, Laia author Ortega Ribera, Martí author Fernández Iglesias, Anabel author Marí, Montserrat author Bosch, Jaime author Gracia Sancho, Jordi author 2021-04-08T09:58:13Z 2021-04-08T09:58:13Z 2019-10-03 2021-04-08T09:58:13Z Inflammation and oxidative stress play a key role in the pathophysiology of advanced chronic liver disease (ACLD) and portal hypertension (PH). Considering the current lack of effective treatments, we evaluated an anti-inflammatory and antioxidant nutraceutical rich in docosahexaenoic acid (DHA) as a possible therapy for ACLD. We investigated the effects of two-week DHA supplementation (500 mg/kg) on hepatic fatty acids, PH, oxidative stress, inflammation, and hepatic stellate cell (HSC) phenotype in rats with ACLD. Additionally, the effects of DHA were evaluated in murine macrophages and human HSC. In contrast to vehicle-treated animals, cirrhotic rats receiving DHA reestablished a healthy hepatic fatty acid profile, which was associated with an improvement in PH. The mechanisms underlying this hemodynamic improvement included a reduction in oxidative stress and inflammation, as well as a marked HSC deactivation, confirmed in human HSC. Experiments with cultured macrophages showed that treatment with DHA protects against pro-inflammatory insults. The present preclinical study demonstrates that a nutraceutical rich in DHA significantly improves PH in chronic liver disease mainly by suppressing inflammation and oxidative stress-driven HSC activation, encouraging its evaluation as a new treatment for PH and cirrhosis. Malalties del fetge Hipertensió portal Cirrosi hepàtica Liver diseases Portal hypertension Hepatic cirrhosis A Nutraceutical Rich in Docosahexaenoic Acid Improves Portal Hypertension in a Preclinical Model of Advanced Chronic Liver Disease